Cover Image


Biosimilars: US Payer Perspectives

出版商 FirstWord 商品編碼 328749
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
生技仿製藥:美國保險者的展望 Biosimilars: US Payer Perspectives
出版日期: 2015年04月01日 內容資訊: 英文


本報告提供美國的生技藥品市場相關資料,包含藥物供給管理 (PBM:Pharmacy Benefit Manager) 、管理護理組織及整合遞送網路的,多樣組織的12個保險者的詳細內容且實用的洞察。


  • 依據計劃著重降低生技藥品治療成本的保險者,為了抑制會員的減少,期望降低成本到哪個程度
  • 在美國認為是利用生技仿製藥的最大促進要素、阻礙要素的保險者確認,還有美國醫療保險設計、保險者的活動如何形成生技仿製藥市場
  • 包含價格策略、教育工作、 醫生的參與及臨床資料的提供,保險者認為美國的生技仿製藥市場上重要的成功要素是什麼
  • 含現代胰島素、Filgrastim、紅血球生成素Alpha、腫瘤 mAb及非腫瘤 mAb、5個產品級的潛在價格、市場佔有率及商務來源的基準
Product Code: 596200355

Biosimilars: US Payer Perspectives pulls back the curtain on the US biologics market and provides detailed and actionable insights from 12 expert US payers from a range of different organisations, including Pharmacy Benefit Managers, Managed Care Organisations and Integrated Delivery Networks. In addition, receive an Advisory Highlights management summary which covers key findings from the report.

Spending on biologics is set to reach $100 billion in the US over the next couple of years, and biosimilars are seen as a potential safety valve that can relieve some of the pressure on a healthcare system that is creaking under the weight of declining resources, increasing demands and expensive new product launches.

Caught in the middle of this are the payers, an important stakeholder group whose voice and insight is critically important in understanding the opportunities, challenges and critical success factors that companies operating in the US biosimilars market need to know and understand.

With the US lagging behind many other developed nations in terms of making biosimilars available to its healthcare system, it's perhaps ironic that recent events have put opportunities and challenges within the US biosimilars market firmly on the pharma industry's radar. Five 351(k) submissions have now been made to the FDA, and a biosimilar has been approved - filgrastim-sndz from Sandoz, called Zarxio. Companies are partnering and acquiring assets that will allow them to maximise the opportunities, and investors in biosimilar companies have been cheered by share price surges and forecasts from some leading investment banks claiming that biosimilars in the US are on the cusp of greatness.

Biosimilars: US Payer Perspectives provides a much needed tonic to perhaps the overly optimistic sentiment that has seeped into the discussions about the US biosimilars opportunity. Critically it provides unique payer insights on some of the critical market shaping issues that are dominating discussions, including pricing, substitution, switching, indication extrapolation, naming and originator company defensive tactics.

The US market holds many opportunities for biosimilar developers, but in order to leverage these opportunities and maximise chances of success, biosimilar developers and originator companies must read this report to understand what payers really think, and how they will act in response to cheaper biologics becoming available.

Top Takeaways

  • Understand what payers are focused on in their efforts to cut the costs of biologic therapies on their plans, and how they would prefer to make savings in order to limit disruption to their members
  • Identify what payers perceive as the biggest drivers and resistors to biosimilar usage in the US, and how health plan design and payer activities could shape the biosimilars market in the US
  • Learn what payers believe are the critical success factors in the US biosimilars market, including pricing strategies, educational efforts, physician engagement and provision of clinical data
  • Benchmark potential pricing, market share and source of business across five key classes of product, including modern insulin, filgrastim, EPO-alfa, oncology mAbs and non-oncology mAbs

Get Answers to Critical Questions

  • What current strategies for cost-containment in biologic therapy are being used by payers in the US?
  • How do payers expect to manage inclusion of biosimilars on to their formularies, and what critical pieces of information will they need to see before making any decisions?
  • From the payers' perspective, what are the current levels of awareness, familiarity and acceptance of biosimilars at the payer and physician level, both personally and generally across each stakeholder group?
  • What do payers see as the key drivers and resistors of biosimilar usage in the US?
  • Do payers agree with the current US Food and Drug Administration (FDA) requirements for biosimilars, and what are their expectations for future regulatory refinements?
  • What do US payers see as the most important reimbursement challenges for biosimilars, including insights on rebating and payment models?
  • How do payers expect pricing dynamics within the US biosimilars market to evolve, and what are their expectations in relation to the pricing of originator biologics in response to biosimilar competition?
  • What are the views of US payers in relation to the key market shaping issues of switching, automatic substitution, extrapolation of indications and biosimilar naming?
  • What do US payers see as the critical success factors for the US biosimilars market, both from a biosimilar and originator biologic manufacturer perspective?
  • Request Sample Pages

Experts Interviewed

FirstWord interviewed 12 payers and also sought the opinions of a range of commercial, regulatory, legal and clinical experts to deliver contemporary, actionable and robust insight on the US biosimilars market:

  • Pharmacy Director, Health Plan Division; Pharmacy Benefit Manager
  • Chief Medical Officer & Chair of P&T Committee; Regional Health Plan
  • VP, Pharmacy Services; Managed Care Organisation
  • Executive VP, Rx Analytics; Pharmacy Benefit Manager
  • Chief Medical Officer; Integrated Delivery Network
  • VP, Formulary Management; Medicaid Plan
  • National Senior Medical Director; Managed Care Organisation
  • Pharmacy Director; Managed Care Organisation
  • Medical Director; Managed Care Organisation
  • Chief Pharmacy Officer; Pharmacy Benefit Manager
  • Pharmacy Director; Regional Health Plan
  • Pharmacy Director; Managed Care Organisation
Back to Top